From Health Canada:
Encysive Pharmaceuticals Inc., in consultation with Health Canada, wishes to highlight important safety information for the safe and appropriate prescribing and use of THELIN™ (sitaxsentan sodium).
THELIN (sitaxsentan sodium) is indicated for treatment of primary pulmonary arterial hypertension or pulmonary hypertension secondary to connective tissue disease, in patients with WHO functional class III who have not responded to conventional therapy. THELIN is also indicated in patients with WHO functional class II who did not respond to conventional therapy and for whom no appropriate alternative can be identified.
For Health Professionals
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment